文献速递心脑血管急症

冠状动脉旁路移植术后抗血小板治疗:随机DACAB试验五年随访

Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial.
PubMed 文献 · BMJ · 2024-06-11
一句话结论DACAB五年随访显示,CABG术后替格瑞洛双联抗血小板治疗一年较阿司匹林单药或替格瑞洛单药降低五年主要不良心血管事件风险。

DACAB试验五年随访纳入中国六家三级医院500例18-80岁择期冠状动脉旁路移植术患者,随机1:1:1接受替格瑞洛90 mg每日两次联合阿司匹林100 mg每日一次(双联抗血小板,n=168)、替格瑞洛单药90 mg每日两次(n=166)或阿司匹林单药100 mg每日一次(n=166)治疗一年,之后按标准诊疗由治疗医生处方抗血小板治疗。主要终点为主要不良心血管事件(全因死亡、心肌梗死、卒中、冠状动脉血运重建的复合终点),意向性治疗分析。五年时477例(95.4%)完成主要不良心血管事件随访,148例发生主要不良心血管事件:双联组39例、替格瑞洛单药组54例、阿司匹林单药组55例。双联组五年主要不良心血管事件风险显著低于阿司匹林单药组(22.6% vs 29.9%;HR 0.65,95%CI 0.43-0.99;P=0.04),也低于替格瑞洛单药组(22.6% vs 32.9%;HR 0.66,95%CI 0.44-1.00;P=0.05),所有敏感性分析结果一致。

要点

  • DACAB五年随访:CABG术后替格瑞洛双联抗血小板治疗一年,五年主要不良心血管事件22.6%,低于阿司匹林单药的29.9%(HR 0.65,95%CI 0.43-0.99;P=0.04)。
  • 双联组五年主要不良心血管事件22.6%,低于替格瑞洛单药组的32.9%(HR 0.66,95%CI 0.44-1.00;P=0.05)。
  • 主要终点为全因死亡、心肌梗死、卒中、冠状动脉血运重建的复合终点,意向性治疗分析,所有敏感性分析结果一致。
  • 五年时477/500例(95.4%)完成主要不良心血管事件随访;148例发生主要不良心血管事件,双联组39例、替格瑞洛单药组54例、阿司匹林单药组55例。
  • 术后第一年干预为替格瑞洛90 mg每日两次联合阿司匹林100 mg每日一次、替格瑞洛单药90 mg每日两次或阿司匹林单药100 mg每日一次;一年后按标准诊疗由治疗医生处方抗血小板治疗。

适用人群与场景

  • 18-80岁(含91例(18.2%)女性)接受择期冠状动脉旁路移植术并完成DACAB试验的500例患者。
  • 中国六家三级医院,入组时间2014年7月至2015年11月,五年随访完成时间2019年8月至2021年6月。

处置流程与药物剂量

  • 术后第一年随机1:1:1接受替格瑞洛90 mg每日两次联合阿司匹林100 mg每日一次(双联抗血小板治疗;n=168)、替格瑞洛单药90 mg每日两次(n=166)或阿司匹林单药100 mg每日一次(n=166)。
  • 术后第一年之后,抗血小板治疗由治疗医生按标准诊疗处方。

研究设计与关键结果

  • 研究类型:随机DACAB试验的五年随访;样本量500例;中国六家三级医院;人群为18-80岁接受择期冠状动脉旁路移植术并完成DACAB试验的患者。
  • 干预与对照:替格瑞洛90 mg每日两次联合阿司匹林100 mg每日一次(n=168)vs 替格瑞洛单药90 mg每日两次(n=166)vs 阿司匹林单药100 mg每日一次(n=166),疗程一年;一年后按标准诊疗处方抗血小板治疗。
  • 主要终点:主要不良心血管事件(全因死亡、心肌梗死、卒中、冠状动脉血运重建的复合终点);五年时477/500例(95.4%)完成随访,148例发生主要不良心血管事件,双联组39例、替格瑞洛单药组54例、阿司匹林单药组55例。
  • 双联组 vs 阿司匹林单药组五年主要不良心血管事件:22.6% vs 29.9%;HR 0.65,95%CI 0.43-0.99;P=0.04。
  • 双联组 vs 替格瑞洛单药组五年主要不良心血管事件:22.6% vs 32.9%;HR 0.66,95%CI 0.44-1.00;P=0.05。
  • 所有敏感性分析结果一致。

证据类型、等级与局限

  • 证据类型:随机对照试验(DACAB)的五年随访;意向性治疗分析;事后敏感性分析检验稳健性。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,冠状动脉旁路移植术后替格瑞洛双联抗血小板治疗一年,较阿司匹林单药或替格瑞洛单药降低五年主要不良心血管事件风险(双联组22.6% vs 阿司匹林单药组29.9%,HR 0.65,95%CI 0.43-0.99,P=0.04;vs 替格瑞洛单药组32.9%,HR 0.66,95%CI 0.44-1.00,P=0.05)。
  • 术后第一年之后抗血小板治疗由治疗医生按标准诊疗处方,五年结局反映第一年随机治疗策略的长期影响。

指南或共识出处

  • DACAB试验(Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Grafting),注册号NCT03987373。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To assess the effect of different antiplatelet strategies on clinical outcomes after coronary artery bypass grafting.

DESIGN: Five year follow-up of randomised Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Grafting (DACAB) trial.

SETTING: Six tertiary hospitals in China; enrolment between July 2014 and November 2015; completion of five year follow-up from August 2019 to June 2021.

PARTICIPANTS: 500 patients aged 18-80 years (including 91 (18.2%) women) who had elective coronary artery bypass grafting surgery and completed the DACAB trial.

INTERVENTIONS: Patients were randomised 1:1:1 to ticagrelor 90 mg twice daily plus aspirin 100 mg once daily (dual antiplatelet therapy; n=168), ticagrelor monotherapy 90 mg twice daily (n=166), or aspirin monotherapy 100 mg once daily (n=166) for one year after surgery. After the first year, antiplatelet therapy was prescribed according to standard of care by treating physicians.

MAIN OUTCOME MEASURES: The primary outcome was major adverse cardiovascular events (a composite of all cause death, myocardial infarction, stroke, and coronary revascularisation), analysed using the intention-to-treat principle. Time-to-event analysis was used to compare the risk between treatment groups. Multiple post hoc sensitivity analyses examined the robustness of the findings.

RESULTS: Follow-up at five years for major adverse cardiovascular events was completed for 477 (95.4%) of 500 patients; 148 patients had major adverse cardiovascular events, including 39 in the dual antiplatelet therapy group, 54 in the ticagrelor monotherapy group, and 55 in the aspirin monotherapy group. Risk of major adverse cardiovascular events at five years was significantly lower with dual antiplatelet therapy versus aspirin monotherapy (22.6% v 29.9%; hazard ratio 0.65, 95% confidence interval 0.43 to 0.99; P=0.04) and versus ticagrelor monotherapy (22.6% v 32.9%; 0.66, 0.44 to 1.00; P=0.05). Results were consistent in all sensitivity analyses.

CONCLUSIONS: Treatment with ticagrelor dual antiplatelet therapy for one year after surgery reduced the risk of major adverse cardiovascular events at five years after coronary artery bypass grafting compared with aspirin monotherapy or ticagrelor monotherapy.

TRIAL REGISTRATION: NCT03987373ClinicalTrials.gov NCT03987373.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Zhu Y, Zhang W, Dimagli A, et al. Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial. BMJ. 2024. PMID: 38862179. doi:10.1136/bmj-2023-075707

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。